Startup developing a blood test for cancer that could replace the standard tissue biopsy of today, has emerged from stealth mode and announced it raised $10 million from Sequoia Capital (and undisclosed other investors) last year.

Guardant Health was founded by a group of individuals who thought that next-generation sequencing artfully applied could create fundamental shifts in the quality of healthcare, especially for cancer. They realized that exponential decreases in sequencing costs alone, although seemingly disruptive, were insufficient to help solve problems that have continued to plague cancer care. Using their expertise as pioneers in the fields of digital signal processing, next-generation sequencing and rare genomics, they developed Guardant's core technology with an architecture that could continually maximally leverage any advances in next-generation sequencing and bioinformatics to ensure the highest performance possible today as well as tomorrow.